This review summarizes the current knowledge on RAAS blockade and NP-augmenting drugs as single or combined strategies in HF. We will discuss challenges that have been met with some of these compounds and novel therapeutic agents currently being evaluated, which could strengthen our pharmacological armamentarium for HF.
|Pages (from-to)||594 - 605|
|Number of pages||12|
|Journal||Circulation: Heart Failure|
|Publication status||Published - 2013|